STOCK TITAN
  1. Home
  2. SEC-Filings
  3. CASI

Casi Pharmaceuticals Inc SEC Filings

CASI NASDAQ

Welcome to our dedicated page for Casi Pharmaceuticals SEC filings (Ticker: CASI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Tracking how CAR-T hopeful CNCT-19 or anti-CD38 antibody CID-103 might reshape future revenue is difficult when CASI Pharmaceuticals disclosures stretch across dozens of forms. Even the most diligent reader of the CASI Pharmaceuticals annual report 10-K simplified can miss key details on EVOMELA® sales in China, while keeping tabs on CASI Pharmaceuticals insider trading Form 4 transactions adds another layer of complexity.

Stock Titan eliminates that friction. Our AI reviews every CASI Pharmaceuticals quarterly earnings report 10-Q filing, each CASI Pharmaceuticals 8-K material events explained, and the full CASI Pharmaceuticals proxy statement executive compensation the moment EDGAR publishes them. The result: "understanding CASI Pharmaceuticals SEC documents with AI" shifts from aspiration to reality. Need alerts on CASI Pharmaceuticals Form 4 insider transactions real-time? We surface them in seconds, highlighting buys or sells that often precede critical trial readouts.

Put the insights to work:

  • Run CASI Pharmaceuticals earnings report filing analysis to see R&D spend, cash runway, and segment revenue without combing through tables.
  • Track CASI Pharmaceuticals executive stock transactions Form 4 against upcoming regulatory milestones.
  • Get "CASI Pharmaceuticals SEC filings explained simply" summaries for risk factors, pipeline updates, and licensing agreements.

From real-time updates to plain-English explanations, Stock Titan delivers a complete view of CASI’s regulatory narrative—saving hours and empowering faster, better-informed decisions.

Filing

[SCHEDULE 13D/A] CASI Pharmaceuticals, Inc. SEC Filing

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other

FAQ

What is the current stock price of Casi Pharmaceuticals (CASI)?

The current stock price of Casi Pharmaceuticals (CASI) is $1.2 as of June 28, 2025.

What is the market cap of Casi Pharmaceuticals (CASI)?

The market cap of Casi Pharmaceuticals (CASI) is approximately 19.1M.

What is the primary focus of CASI Pharmaceuticals Inc?

CASI Pharmaceuticals focuses on developing, manufacturing, and commercializing innovative therapeutic products, particularly in the fields of oncology, immunology, and hematologic malignancies.

Which therapeutic areas does CASI primarily target?

CASI’s therapeutic focus spans oncology, including multiple myeloma treatment, immune-mediated diseases such as immune thrombocytopenia, and organ transplant rejection, among other unmet medical needs.

How does CASI Pharmaceuticals generate revenue?

The company generates revenue primarily through the commercialization of its approved products, alongside continued investments in research and development for its expanding product pipeline.

What are some key products or candidates in CASI’s portfolio?

Key products include EVOMELA® used in conditioning treatments, FOLOTYN® for lymphoma, and promising pipeline candidates such as CID-103 (an anti-CD38 monoclonal antibody) and CNCT-19 (a CAR-T cell therapy candidate).

How does CASI differentiate itself in the competitive biopharmaceutical market?

CASI differentiates itself through its strategic global presence, combining deep China-based regulatory expertise with robust clinical development processes and a diversified therapeutic portfolio addressing specific unmet patient needs.

What role does clinical research play in CASI’s strategy?

Clinical research is central to CASI’s strategy. The company continuously advances its pipeline through rigorous preclinical and clinical trials while maintaining high standards of scientific validation and regulatory compliance.

How does CASI navigate complex regulatory environments?

CASI leverages its strong regulatory expertise, particularly in China and the United States, to obtain necessary approvals and ensure that its products meet stringent regulatory standards across multiple jurisdictions.

What is the significance of CASI’s global commercial strategy?

The global commercial strategy allows CASI to tap into diverse markets by aligning local regulatory insights with global drug development practices, thereby enhancing the commercial viability and adoption of its therapeutic products.

Can you explain CASI's approach to innovation?

CASI’s approach to innovation centers on a well-rounded product pipeline that combines established therapies with novel therapeutic candidates, thereby addressing current unmet needs while paving the way for future breakthroughs in patient care.

How does transparency factor into CASI’s operations?

Transparency is integral to CASI's operations. The company maintains open communication through regular updates on clinical progress and business performance, building trust with investors, regulators, and healthcare professionals alike.
Stock CASI logo
Casi Pharmaceuticals Inc

NASDAQ:CASI

CASI Rankings

#5564 Ranked by Market Cap
N/A Ranked by Dividends

CASI Stock Data

19.06M
7.38M
47.92%
26.69%
0.18%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
China
ROCKVILLE